Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 11/20 | 0.56 |
| ▸ | BRAF | P15056 | 5/20 | 0.56 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.52 |
| ▸ | TEK | Q02763 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL936531 | 0.91 | MAPK14 (0.54) | RAF1BRAFKDREPHB4TEK | |
| SCHEMBL4239060 | 0.90 | RAF1 (0.59) | RAF1BRAFKDRTEKMAPT | |
| SCHEMBL937292 | 0.87 | RAF1 (0.67) | RAF1BRAFKDRMAPK14TNNI3K | |
| SCHEMBL13556578 | 0.87 | BRAF (0.55) | RAF1BRAFKDRMAPK14TNNI3K | |
| SCHEMBL4464158 | 0.83 | RAF1 (0.68) | RAF1BRAFKDRMAPK14TNNI3K | |
| SCHEMBL8370028 | 0.83 | GRIK1 (0.65) | RAF1KDRMEN1MAPTKMT2A | |
| SCHEMBL4243364 | 0.81 | MAPT (0.57) | RAF1MAPK14MEN1MAPTKMT2A | |
| SCHEMBL939518 | 0.79 | RAF1 (0.75) | RAF1BRAFKDRTEKMAPK14 | |
| SCHEMBL938321 | 0.79 | RAF1 (0.74) | RAF1BRAFKDRMAPK14TNNI3K | |
| SCHEMBL620478 | 0.78 | RAB9A (0.69) | RAF1MEN1MAPTKMT2ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838541-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE, LLC (US) | 2010-11-23 | — | — | US | claimed |
| US-20090093526-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER HEALTHCARE LLC | 2009-04-09 | — | — | US | claimed |
| EP-1616865-A1 | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | Bayer Pharmaceuticals Corporation (US) | 2006-01-18 | — | — | EP | claimed |
| EP-1042305-B1 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER PHARMACEUTICALS CORP (US) | 2005-06-08 | — | — | EP | claimed |
| US-20040102636-A1 | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | BAYER CORPORATION | 2004-05-27 | — | — | US | claimed |
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2018-10-18 | — | — | US | disclosed |
| US-20160015697-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2016-01-21 | — | — | US | disclosed |
| US-8618141-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120289552-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120270878-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER HEALTHERCARE LLC (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270878-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER HEALTHERCARE LLC (US) | 2012-10-25 | — | — | US | disclosed |
| WO-2004019873-A9 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040102636-A1 | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | BAYER CORPORATION | 2004-05-27 | — | — | US | disclosed |
| WO-2004024083-A2 | METHODS OF BONE HEALING | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004021988-A2 | TREATMENT OF PAIN BY INHIBITION OF P38 MAP KINASE | SCIOS INC. (US) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004019873-A2 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| CN-1283180-A | Inhibition of raf kinase using symmerical and unsymmerical substituted diphenyl ureas | BAYER AG (US) | 2001-02-07 | — | — | CN | disclosed |
| EP-1049664-A1 | INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS | Bayer Corporation (US) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999032436-A1 | INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093526-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | MAP2K2, MAPK1, MAP2K1 | RAF1 514/4885BRAF 532/4885KDR 3299/4885 |
| US-20040102636-A1 | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas | MAP2K2, MAPK1, MAP2K1 | RAF1 514/4885BRAF 532/4885KDR 3299/4885 |
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | RAF1 867/4885BRAF 487/4885KDR 3/4885 |
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | FLT1, FLT4, KDR | RAF1 867/4885BRAF 487/4885KDR 3/4885 |
| US-20120270878-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | MAP2K2, MAPK1, MAP2K1 | RAF1 514/4885BRAF 532/4885KDR 3299/4885 |
| US-20120289552-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | FLT4, FLT1, KDR | RAF1 817/4885BRAF 290/4885KDR 3/4885 |
| US-20160015697-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | RAF1 867/4885BRAF 487/4885KDR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.